- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04790851
Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4
A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Beijing) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)
Subjects will be recruited and divided into 3 groups:
Experimental Group (384 subjects): 1st dose : combined vaccination of COVAX+IIV4, 2nd dose: combined vaccination of COVAX+PPV23; Control Group A (384 subjects): 1st dose: COVAX only, 2nd dose: COVAX only; Control Group B (384 subjects): 1st dose: IIV4 only, 2nd dose: PPV23 only.
Blood samples will be collected 3 times:
before the 1st dose of vaccinatioin; before the 2nd dose of vaccination; 28 days after the 2nd dose of vaccination.
The immunogenicity and safety of both experimental and control groups will be analyzed.
Study Overview
Status
Conditions
Detailed Description
This randomized, parallel, controlled study is designed to evaluate the immunogenicity and safety of simultaneously immunization of COVAX + PPV23 and COVAX + IIV4.
1152 subjects are divided into 3 groups, including 1 experimental group and 2 control groups (control group A and B). Each group includes 384 subjects respectively.
Experimental Group (384 subjects) will receive: 1st dose : combined vaccination of COVAX+IIV4, 2nd dose: combined vaccination of COVAX+PPV23; Control Group A (384 subjects) will receive: 1st dose: COVAX only, 2nd dose: COVAX only; Control Group B (384 subjects) will receive: 1st dose: IIV4 only, 2nd dose: PPV23 only.
Specifically, each group will be divided again. Each 384-subject group is divided again into 2 age-based subgroups: (1) 18-59 years old; (2) ≥60 years old.
Each subgroup includes 192 subjects respectively. Blood samples will be collected 3 times: (1) before the 1st dose of vaccinatioin; (2) before the 2nd dose of vaccination; (3) 28 days after the 2nd dose of vaccination.
To evaluate the immunogenicity, the investigators will detect and compare the neutralizing antibody levels, the seroconversion rates and antibody geometric mean concentrations.
The safety of all groups will be monitored as well.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Chengdu, China, 610041
- Sichuan Center for Disease Control and Prevention
-
Shanghai, China, 200336
- Shanghai Municipal Center for Disease Control and Prevention
-
Taiyuan, China, 030012
- Shanxi Provincial Center for Disease Control and Prevention
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- ≥18 years old when enrolled;
- Participants signing the informed consent;
- Being able to participate in all planned follow-ups and accomplish all research procedures including completing a diary card and coming back for interview;
- Having not been administered any pneumonia vaccine or COVID-19 vaccine, and having not been administered an influenza vaccine in the current season before enrollment;
- ≥14 days from the most recent vaccination;
- Before enrollment, the body temperature is ≤37.0C as confirmed by medical history and clinical examination.
Exclusion criteria for the first dose:
- Having a history of COVID-19 or a positive nucleic acid test for COVID-19;
- Having a history or a family history of allergy, convulsion, epilepsy, brain disease, or mental illness;
- Being allergic to any component of vaccines, or having a history of severe allergic reaction to any vaccine;
- Having immunodeficiency disorder, during treatment of malignant tumor, having immunodeficiency induced by immunosuppressants (oral steroid hormones) or HIV, or having a family member with close contact who suffers from congenital immune disorder;
- Having injection of non-specific immunoglobulin within 1 month prior to enrollment;
- Having acute febrile illness or communicable disease;
- Having a history of confirmed thrombocytopenia or other coagulation disorders, which may cause contraindications for a subcutaneous injection;
- Having severe chronic disease or acute exacerbation of chronic disease, or having uncontrolled hypertension or diabetes;
- Having various infectious, pyogenic, or allergic skin diseases;
- Women in pregnancy or lactation or participants who plan for a baby within 3 months after vaccination should delay the vaccination;
- Having any condition that may affect trial assessment as determined by researchers.
Exclusion criteria for the second dose:
- Having any serious adverse event related to the first dose vaccination;
- After vaccination, having systemic adverse reaction or allergic reaction with a severity of grade 3 or higher as determined by researchers;
- Having a newly emerging condition that meets the exclusion criteria for the first dose;
- Having any condition that may affect trial assessment as determined by researchers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental group
Experimental Group (384 subjects) will receive: 1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23
|
1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23
|
Active Comparator: Control group A
Control Group A (384 subjects) will receive: 1st dose: COVAX only; 2nd dose: COVAX only
|
1st dose: COVAX only; 2nd dose: COVAX only
|
Active Comparator: Control group B
Control Group B (384 subjects) will receive: 1st dose: IIV4 only; 2nd dose: PPV23 only
|
1st dose: IIV4 only; 2nd dose: PPV23 only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seroconversion rate (COVAX)
Time Frame: Results obtained 28 days after the first dose (= right before the second dose)
|
the rate of positive seroconversion against coronavirus
|
Results obtained 28 days after the first dose (= right before the second dose)
|
Seroconversion rate (COVAX)
Time Frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
|
the rate of positive seroconversion against coronavirus
|
Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
|
Neutralizing antibody level (COVAX)
Time Frame: Baseline (before vaccination) results
|
neutralizing antibody level against coronavirus
|
Baseline (before vaccination) results
|
Neutralizing antibody level (COVAX)
Time Frame: Results obtained 28 days after the first dose (= right before the second dose)
|
neutralizing antibody level against coronavirus
|
Results obtained 28 days after the first dose (= right before the second dose)
|
Neutralizing antibody level (COVAX)
Time Frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
|
neutralizing antibody level against coronavirus
|
Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
|
Seropositive rate (IIV4)
Time Frame: Baseline (before vaccination) results
|
the rate of positive seroconversion against influenza A (H3N2, H1N1) type and B (BY, BV) type viruses
|
Baseline (before vaccination) results
|
Seroconversion rate (IIV4)
Time Frame: Results obtained 28 days after the first dose (= right before the second dose)
|
the rate of positive seroconversion against influenza A (H3N2, H1N1) type and B (BY, BV) type viruses
|
Results obtained 28 days after the first dose (= right before the second dose)
|
Seroconversion rate (IIV4)
Time Frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
|
the rate of positive seroconversion against influenza A (H3N2, H1N1) type and B (BY, BV) type viruses
|
Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
|
Hemmagglution inhibition antibody level (IIV4)
Time Frame: Baseline (before vaccination) results
|
Hemmagglution inhibition antibody levels against influenza A (H3N2, H1N1) type and B (BY, BV) type viruses
|
Baseline (before vaccination) results
|
Hemmagglution inhibition antibody level (IIV4)
Time Frame: Results obtained 28 days after the first dose (= right before the second dose)
|
Hemmagglution inhibition antibody levels against influenza A (H3N2, H1N1) type and B (BY, BV) type viruses
|
Results obtained 28 days after the first dose (= right before the second dose)
|
Hemmagglution inhibition antibody level (IIV4)
Time Frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
|
Hemmagglution inhibition antibody levels against influenza A (H3N2, H1N1) type and B (BY, BV) type viruses
|
Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
|
Seroconversion rate (PPV23)
Time Frame: Results obtained 28 days after the first dose (= right before the second dose)
|
the rate of positive seroconversion against 23 pneumococcal serotypes
|
Results obtained 28 days after the first dose (= right before the second dose)
|
Seroconversion rate (PPV23)
Time Frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
|
the rate of positive seroconversion against 23 pneumococcal serotypes
|
Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
|
Neutralizing antibody level (PPV23)
Time Frame: Baseline (before vaccination) results
|
Neutralizing antibody level against 23 pneumococcal serotypes
|
Baseline (before vaccination) results
|
Neutralizing antibody level (PPV23)
Time Frame: Results obtained 28 days after the first dose (= right before the second dose)
|
Neutralizing antibody level against 23 pneumococcal serotypes
|
Results obtained 28 days after the first dose (= right before the second dose)
|
Neutralizing antibody level (PPV23)
Time Frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
|
Neutralizing antibody level against 23 pneumococcal serotypes
|
Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events following vaccination
Time Frame: 0-6 months
|
analyse the incidence of adverse events following immunization, both solicited and unsolicited
|
0-6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Xiaodong Sun, Shanghai Municipal Center for Disease Control and Prevention
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Streptococcal Infections
- Gram-Positive Bacterial Infections
- Pneumonia, Bacterial
- Orthomyxoviridae Infections
- Pneumococcal Infections
- COVID-19
- Pneumonia, Pneumococcal
- Influenza, Human
Other Study ID Numbers
- COVAX+PPV23+IIV4-Beijing
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on COVAX only (1st and 2nd dose)
-
China National Biotec Group Company LimitedWuhan Institute of Biological Products Co., Ltd; Henan Center for Disease Control... and other collaboratorsActive, not recruitingPneumonia, Pneumococcal | Influenza, Human | COVID-19 PneumoniaChina
-
University of Texas Southwestern Medical CenterCompletedDry Eye DiseaseUnited States
-
Children's Hospital of PhiladelphiaRegeneron Pharmaceuticals; Genzyme, a Sanofi CompanyRecruitingEosinophilic EsophagitisUnited States
-
Danderyd HospitalUmeå University; Sahlgrenska University Hospital, Sweden; University of TsukubaCompletedStroke | Hemiparesis | Ambulation DifficultySweden
-
Duke UniversityCenters for Disease Control and PreventionCompletedCervical Cancer | Genital WartsUnited States
-
Bandim Health ProjectMurdoch Childrens Research InstituteCompleted
-
Syamsudin Abdillah,Ph.D, Pharm DApt. Dian Yudianto; Dr. dr Erni J. Nelwan, Sp.PD, Ph.D; Apt.Hesty Utami Ramadaniati...CompletedUncomplicated Plasmodium FalciparumIndonesia
-
Inonu UniversityNot yet recruiting
-
Pediatric Clinical Research PlatformGeneva Emergency Medical Services, Geneva, Switzerland; Lausanne Emergency... and other collaboratorsCompletedReducing Prehospital Medication Errors & Time to Drug Delivery by EMS During Simulated Pediatric CPREmergency Medical Services | Pediatrics | Resuscitation | Cardiopulmonary Arrest | Medication ErrorsSwitzerland
-
Novartis PharmaceuticalsTerminatedCarcinoma, Renal CellAustralia, Korea, Republic of